Graves' orbitopathy treated with immunosuppressive therapy and orbital radiotherapy in a tertiary care endocrine centre: case series

Graves’ Orbitopathy (GO) is a localized entity of Graves’ disease, which is a challenging disease to treat. We describe 6 cases of moderate to severe GO who presented to our endocrine centre, with a mean age of 48.6 years and equal gender distribution. All of them were thyrotoxic before the presentation and were treated with antithyroid drugs. CT scans of orbits in 5 patients were consistent with GO. All of the patients were treated with intravenous methylprednisolone pulse therapy for a duration of 12 weeks and orbital radiotherapy for two weeks according to European Groups on Graves' Orbitopathy (EUGOGO) guideline. All six patients went into remission and remained so after one year of follow-up. Combination therapy seems to be effective in treating moderate to severe GO